Kawakami K - Search Results

1

Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain.

Kawakami K, Joshi BH, Puri RK. Kawakami K, et al. Hum Gene Ther. 2000 Sep 1;11(13):1829-35. doi: 10.1089/10430340050129459. Hum Gene Ther. 2000. PMID: 10986556

2

Internalization property of interleukin-4 receptor alpha chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells.

Kawakami K, Kawakami M, Leland P, Puri RK. Kawakami K, et al. Among authors: kawakami m. Clin Cancer Res. 2002 Jan;8(1):258-66. Clin Cancer Res. 2002. PMID: 11801567

3

Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells.

Kawakami M, Kawakami K, Puri RK. Kawakami M, et al. Among authors: kawakami k. Cancer Immunol Immunother. 2002 Feb;50(12):691-700. doi: 10.1007/s00262-001-0242-6. Epub 2001 Dec 7. Cancer Immunol Immunother. 2002. PMID: 11862421 Free PMC article.

4

Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.

Joshi BH, Kawakami K, Leland P, Puri RK. Joshi BH, et al. Among authors: kawakami k. Clin Cancer Res. 2002 Jun;8(6):1948-56. Clin Cancer Res. 2002. PMID: 12060640

5

Targeting interleukin-4 receptors for effective pancreatic cancer therapy.

Kawakami K, Kawakami M, Husain SR, Puri RK. Kawakami K, et al. Among authors: kawakami m. Cancer Res. 2002 Jul 1;62(13):3575-80. Cancer Res. 2002. PMID: 12097255

6

Cytokine receptor as a sensitizer for targeted cancer therapy.

Kawakami K, Kawakami M, Puri RK. Kawakami K, et al. Among authors: kawakami m. Anticancer Drugs. 2002 Aug;13(7):693-9. doi: 10.1097/00001813-200208000-00003. Anticancer Drugs. 2002. PMID: 12187325 Review.

7

Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.

Kawakami M, Kawakami K, Stepensky VA, Maki RA, Robin H, Muller W, Husain SR, Puri RK. Kawakami M, et al. Among authors: kawakami k. Clin Cancer Res. 2002 Nov;8(11):3503-11. Clin Cancer Res. 2002. PMID: 12429641

8

Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.

Kawakami K, Husain SR, Kawakami M, Puri RK. Kawakami K, et al. Among authors: kawakami m. Mol Med. 2002 Aug;8(8):487-94. Mol Med. 2002. PMID: 12435859 Free PMC article.

9

Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways.

Kawakami M, Kawakami K, Puri RK. Kawakami M, et al. Among authors: kawakami k. Int J Cancer. 2003 Jan 1;103(1):45-52. doi: 10.1002/ijc.10778. Int J Cancer. 2003. PMID: 12455052

10

IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer.

Kawakami K, Kawakami M, Puri RK. Kawakami K, et al. Among authors: kawakami m. J Immunol. 2002 Dec 15;169(12):7119-26. doi: 10.4049/jimmunol.169.12.7119. J Immunol. 2002. PMID: 12471149

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,691 results

Search Page

Filters